Afya stock drops as planned merger threatens direct US market access
A binding merger agreement between Brazilian medical education giant Afya and rival Yduqs will result in Nasdaq delisting, ending direct US retail access.
The unique direct channel for US retail investors to buy into Brazil’s highly lucrative medical education sector is operating on borrowed time. On September 23, 2026, the Minas Gerais-based medical education giant Afya Limited announced it had entered into a binding merger agreement with its major Brazilian higher education rival, Yduqs Participações S.A.. The transaction will combine the two companies into a massive education group serving approximately 1.6 million students, with pro-forma annual revenues of 9.4 billion reais ($1.7 billion).
The announcement of the deal triggered immediate pressure on Afya’s stock, which fell over 5% to trade at $12.32 on Nasdaq as investors reacted to the planned termination of the company's US listing. Unlike most Brazilian corporate heavyweights that trade in New York via American Depositary Receipts (ADRs), Afya chose a direct primary listing on Nasdaq in 2019. This direct listing has served as a friction-free gateway for foreign retail investors seeking exposure to Brazil's domestic economy without navigating complex international brokerage accounts.
Under the terms of the definitive agreement, Afya will merge into Yduqs, with Yduqs continuing as the surviving holding company. Once the transaction is finalized, the combined entity will be listed exclusively on the Novo Mercado segment of Brazil's local B3 exchange in São Paulo. Consequently, Afya’s Class A common shares will be delisted from Nasdaq, closing off direct US trading access.
The corporate restructuring is currently navigating regulatory and corporate hurdles. The merger requires formal approval from the shareholders of both companies at extraordinary general meetings. It also requires antitrust clearance from Brazil's Administrative Council for Economic Defense (CADE), to which the transaction must be submitted within 20 business days of signing. The companies have established a long stop date of March 31, 2028, to complete the transaction, giving investors a clear timeline for the transition.
What it touches
The upcoming delisting directly exposes holders of Afya (NASDAQ: AFYA) to transaction and structural risks. Under the merger terms, each Afya share will be exchanged for 6.408347 newly issued Yduqs shares (B3: YDUQ3), resulting in Afya shareholders holding a 69% stake in the combined Brazilian entity. Crucially, US retail investors who are not qualified institutional buyers or accredited investors will not receive local Brazilian shares directly. Instead, their share consideration is expected to be sold on the B3 exchange following the closing, with the net cash proceeds distributed to them, making current stock movements highly sensitive to regulatory progress in Brasília.